This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
XELJANZ® (tofacitinib citrate) Prescribing Information and Maxtrex (methotrexate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Tofacitinib should only be used if no suitable treatment alternatives are available in patients:
These risks are considered class effects and relevant across all approved indications of JAKi in inflammatory and dermatologic diseases.
The study concluded that there was not evidence of an increased risk of malignancy development with tofacitinib therapy, in comparison with TNFi therapy, in RA patients treated in a real-world setting. However, the results cannot rule out the possibility of an increase in risk that may accrue with a longer duration of treatment with tofacitinib.
†Primary outcome: Composite malignancy outcome of any new malignancy excluding NMSC. ‡TNFi: Infliximab, adalimumab, certolizumab pegol, etanercept, and golimumab. §Patients from Medicare were ≥65 years old. ║CV risk factors include history of smoking, hypertension, dyslipidemia, diabetes mellitus, IHD, or family history of IHD.
†Primary outcome: Composite malignancy outcome of any new malignancy excluding NMSC. ‡Data shown on this slide is from the as-treated analysis, where patients are censored at treatment discontinuation or switch. §TNFi: Infliximab, adalimumab, certolizumab pegol, etanercept, and golimumab. ║Patients from Medicare were ≥65 years old. ¶CV risk factors include history of smoking, hypertension, dyslipidemia, diabetes mellitus, IHD, or family history of IHD
Table adapted and graph created from Khosrow-Khavar F, et al. 2022.
†Primary outcome: Composite malignancy outcome of any new malignancy excluding NMSC. ‡TNFi: Infliximab, adalimumab, certolizumab pegol, etanercept, and golimumab. §Patients ≥18 years old (≥65 years in Medicare).
Table adapted and graph created from Khosrow-Khavar F, et al. 2022.
†TNFi: infliximab, adalimumab, certolizumab pegol, etanercept, and golimumab. ‡Patients ≥18 years old (≥65 in Medicare), pooled from Optum, MarketScan, and Medicare US claim databases.
Table adapted and graph created from Khosrow-Khavar F, et al. 2022.
Learn more about the ORAL Surveillance trial.
Explore more real-world evidence trials in RA.
CI=confidence interval; CV=cardiovascular; HR=hazard ratio; IHD=ischemic heart disease; NMSC=non-melanoma skin cancer; PS=propensity score; RCT=randomized controlled trial; RWE=real-world evidence; TNFi=tumor necrosis factor inhibitor.
Additional Prescribing Information
Enbrel (etanercept): https://www.pfizerpiindex.co.uk/enbrel
Inflectra (infliximab): https://www.pfizerpiindex.co.uk/inflectra
References
In this video, Dr James Galloway, respected rheumatologist and researcher talks about the ORAL Surveillance study and its implications for the use of tofacitinib in the treatment of RA. He offers an overview of the study design and a summary of the results, before offering his own clinical interpretation and how this affects his prescribing decisions.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021